University of Michigan, Kellogg Eye Center

Summary

University of Michigan, Kellogg Eye Center is a medical facility located in Ann Arbor, Michigan. This center is recognized for care of Retinitis Pigmentosa, Macular Degeneration, Retinal Disease, Eye Diseases, Age-Related Macular Degeneration and other specialties. University of Michigan, Kellogg Eye Center is involved with conducting 77 clinical trials across 98 conditions. There are 8 research doctors associated with this hospital, such as Thiran Jayasundera, MD, Cagri Besirli, Shahzad Mian, MD, and Susan G Elner, MD.

Top PIs

Clinical Trials running at University of Michigan, Kellogg Eye Center

Retinitis Pigmentosa

Retinal Disease

Retinal Dystrophy

Stargardt Disease

Retinal Degeneration

Macular Degeneration

Eye Diseases

Glaucoma

Age-Related Macular Degeneration

Cone Rod Dystrophy

Rare Gene Study

for Retinitis Pigmentosa

This is an international, multicenter study with two components: Registry * A standardized genetic screening and a prospective, standardized, cross-sectional clinical data collection * Enrollment is open to all genes on the RD Rare Gene List Natural History Study * A prospective, standardized, longitudinal Natural History Study * Enrollment opens gene-by-gene, based on funding and within-gene Registry enrollment The study objectives are as follows. Registry Objectives 1. Genotype Characterization 2. Cross-Sectional Phenotype Characterization (within gene) 3. Establish a Link to My Retina Tracker Registry (MRTR) 4. Ancillary Exploratory Studies - Pooling of Genes Natural History Study Objectives 1. Natural History (within gene) 2. Structure-Function Relationship (within gene) 3. Risk Factors for Progression (within gene) 4. Ancillary Exploratory Studies - Pooling of Genes

Recruiting

1 award

N/A

10 criteria

Gene Therapy

for Retinitis Pigmentosa

The purpose of this study is to assess the safety and tolerability of subretinal delivery of Adeno-associated Virus Vector (AAV5 hRKp.RPGR) gene therapy in adults and children with X-linked retinitis pigmentosa.

Recruiting

1 award

Phase 2

VP-001

for Retinal Dystrophy

A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy

Recruiting

1 award

Phase 1

3 criteria